PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment (Cancer Cell, 2009, 15:21-34)

報告日期: 2009/04/24
報告時間: 17:10/18:00
報告學生: 蘇珮\誼(英文報告)
講評老師: 賴明德


PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

Cancer Cell, 15: 21–34 (2009)


Speaker: 蘇珮誼

Commentator: 賴明德  老師

Time: 17:00~18:00, 04/24/2009

Room: 602



Fibroblasts have been reported to be the major component of the stromal cells within various types of human carcinomas, and several studies indicate that VEGF-A, an important angiogenesis factor, would be produced by tumor-associated fibroblasts (TAF) for tumor growth. However, recent studies demonstrate that the TAF-induced may contain both VEGF dependent and VEGF independent mechanisms which cause the tumor to become resistant to anti-VEGF treatment. So, the authors wanted to identify the tumor angiogenesis-inducing factors other than VEGF.  First, the authors compared the gene expression profiles of the fibroblast cell (TAF-EL4) refractory to anti-VEGF treatment and the fibroblast cell (TAF-TIB6) sensitive to anti-VEGF treatment. They found a candidate, PDGF-C, involved in VEGF independent mechanism stimulating angiogenesis and tumor growth. Taken the results together, the authors indicated that the TAF-EL4 but TAF-TIB6 was able to promote the tumor growth under anti-VEGF treatment because of PDGF-C, which is specific for some tumors only. Combination of both anti-PDGF-C and anti-VEGF treatment will be clinically more effective than anti-VEGF treatment alone.



1. Orimo, A., Gupta, P.B., Sgroi, D.C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V.J., Richardson, A.L., and Weinberg, R.A. Cell 121, 335–348 (2005)

2. Li, X., Tjwa, M., Moons, L., Fons, P., Noel, A., Ny, A., Zhou, J.M., Lennartsson,J., Li, H., Luttun, A., J. Clin. Invest. 115, 118–127 (2005)